These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 9256911)

  • 1. Current status of melanoma vaccines.
    Kuhn CA; Hanke CW
    Dermatol Surg; 1997 Aug; 23(8):649-54; discussion 654-5. PubMed ID: 9256911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melanoma vaccines.
    Perales MA; Wolchok JD
    Cancer Invest; 2002; 20(7-8):1012-26. PubMed ID: 12449735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical activity of a polyvalent melanoma antigen vaccine.
    Bystryn JC
    Recent Results Cancer Res; 1995; 139():337-48. PubMed ID: 7597302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of malignant melanoma.
    Kadison AS; Morton DL
    Surg Clin North Am; 2003 Apr; 83(2):343-70. PubMed ID: 12744613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next generation of immunotherapy for melanoma.
    Kirkwood JM; Tarhini AA; Panelli MC; Moschos SJ; Zarour HM; Butterfield LH; Gogas HJ
    J Clin Oncol; 2008 Jul; 26(20):3445-55. PubMed ID: 18612161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanoma antigens and targets for vaccination.
    Kang N; Truman H; Sanders R; Kupsch J
    Br J Hosp Med; 1997 Sep 17-30; 58(6):282-6. PubMed ID: 9488805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy.
    Chung MH; Gupta RK; Hsueh E; Essner R; Ye W; Yee R; Morton DL
    J Clin Oncol; 2003 Jan; 21(2):313-9. PubMed ID: 12525524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine therapy for patients with melanoma.
    Haigh PI; Difronzo LA; Gammon G; Morton DL
    Oncology (Williston Park); 1999 Nov; 13(11):1561-74; discussion 1574 passim. PubMed ID: 10581603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy and experimental approaches for metastatic melanoma.
    Atkins MB
    Hematol Oncol Clin North Am; 1998 Aug; 12(4):877-902, viii. PubMed ID: 9759585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
    Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
    Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.
    Hsueh EC; Morton DL
    Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for advanced melanoma: Current knowledge and future directions.
    Nakamura K; Okuyama R
    J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of melanoma vaccines: active specific immunotherapy for melanoma patients.
    Ollila DW; Kelley MC; Gammon G; Morton DL
    Semin Surg Oncol; 1998 Jun; 14(4):328-36. PubMed ID: 9588726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine therapy for melanoma: current status and future directions.
    Terando AM; Faries MB; Morton DL
    Vaccine; 2007 Sep; 25 Suppl 2():B4-16. PubMed ID: 17646038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for human malignant melanoma.
    Kopf AW
    South Med J; 1975 Apr; 68(4):495-503. PubMed ID: 1124416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanoma vaccines: prim and proper presentation.
    Timmerman JM; Levy R
    Nat Med; 1998 Mar; 4(3):269-70. PubMed ID: 9500593
    [No Abstract]   [Full Text] [Related]  

  • 18. Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines.
    Mocellin S; Rossi CR; Nitti D; Lise M; Marincola FM
    Biochim Biophys Acta; 2003 Dec; 1653(2):61-71. PubMed ID: 14643925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.
    Sondak VK; Sosman JA
    Semin Cancer Biol; 2003 Dec; 13(6):409-15. PubMed ID: 15001159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.
    Belli F; Testori A; Rivoltini L; Maio M; Andreola G; Sertoli MR; Gallino G; Piris A; Cattelan A; Lazzari I; Carrabba M; Scita G; Santantonio C; Pilla L; Tragni G; Lombardo C; Arienti F; Marchianò A; Queirolo P; Bertolini F; Cova A; Lamaj E; Ascani L; Camerini R; Corsi M; Cascinelli N; Lewis JJ; Srivastava P; Parmiani G
    J Clin Oncol; 2002 Oct; 20(20):4169-80. PubMed ID: 12377960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.